VenoStent creates breakthrough technology for dialysis patients


News provided by

Comserve Inc.

Aug 11, 2020, 08:00 EST


Bronx, United States, Aug 11, 2020, 08:00 /Comserve / -- In patients with end-stage renal disease, failed dialysis surgeries occur in around 55% to 65% of the patients. While difficult on one hand, caring for these patients can cost the Medicare and Medicaid Services system around USD 2 billion a year.

Image placeholder

In patients with end-stage renal disease, failed dialysis surgeries occur in around 55% to 65% of the patients. While difficult on one hand, caring for these patients can cost the Medicare and Medicaid Services system around USD 2 billion a year.

Timothy Bouré and his co-founder Geoffrey Lucks were almost broke when they moved to Dallas to join the first accelerator they entered after forming VenoStent. This was a company that aimed to improve outcomes for dialysis patients.

Dialysis surgery patients face a lot of issues when it comes to long term health. VenoStent looks to address these issues with the development of SelfWrap. SelfWrap is a perivascular wrap that has been designed to reduce failures at the vein-graft or vein-artery junction of patients who have undergone dialysis surgery. This product aims to reduce the collapse of the vein at this critical point and also promotes outward vein growth. It also helps provide a custom-fit, flexible, durable mechanical support.

The key discovery that Bouré made (and help set VenoStent apart) was of a new type of polymer that provides support towards cell growth as it heals after a dialysis surgery.

The company has already raised USD 2.4 million is small equity infusions and grant funding. It has also been awarded the KidneyX Prize by the American Society of Nephrology and the Department of Health and Human Services.

The company is moving towards its next round of animal testing and will look to conduct its first human trials by 2021 outside of the United States.

Even though the company is primarily focused on renal failure, the materials that Bouré has created can have applications in other avenues as well. The same material can be used for the large intestine. Bouré believes that the material has a lot of tunability in all of its properties and can be modified according to the problem at hand.

About VenoStent:

A medical device company, VenoStent is a company that works to develop bioresorbable memory polymer that can help reduce dialysis access failures. It was founded in 2016. For more information, please visit - https://www.venostent.com/.

COMSERVE empowers communicators by offering modern digital PR solutions and distribution services to identify and engage with customers, opinion leaders, bloggers and other relevant audience.


For more information, please contact:

Anna R .Moser

Comserve Inc.
Email: info@comserveonline.com
Tel: 859-228-3939

Related Links
https://www.comserveonline.com/



Also from this source


Blackstone readies itself to acquire Ancestry for USD 4.7 billion

Blackstone has announced that it had reached an agreement to acquire Ancestry. This will be done fro


Hurun list values Zerodha at USD 3 billion

The Hurun Research Institute released the Hurun Global Unicorn Index 2020, in association with Suzho